SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Board Changes

25 Sep 2025 07:00

RNS Number : 7148A
Frontier IP Group plc
25 September 2025
 

RNS

AIM: FIPP

25 September 2025

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Announcement of Board Change

 

Frontier IP, a specialist in commercialising intellectual property, today announces that

Matthew White (Chief Commercialisation Officer) has decided to leave the Group to pursue an opportunity as Chief Executive Officer of a Cambridge based early-stage medical devices company.

 

It is currently intended that Mr White will remain with the Company as Chief Commercialisation Officer and an Executive Director of the Company until the end of his six month notice period on 24 March 2026.

 

The Group is in discussions about a successor and a further update will be issued when appropriate.

 

Frontier IP Chief Executive Officer Neil Crabb said: "I am sorry Matt is leaving the Group. His departure is wholly amicable. In the seven years he has been our Chief Commercialisation Officer, he has played an invaluable role in the progress made by Frontier IP and our portfolio companies. I would like to wish him all the best in the exciting role he is to fulfil. I am sure he will be a great success."

 

Frontier IP Chief Commercialisation Officer Matthew White said: "It has been a privilege to be involved in the development of the Frontier IP portfolio over the last seven years. I look forward to the continued success of the portfolio and Frontier IP's growing engagement in the Cambridge deeptech ecosystem."

 

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / Daniel Dearden-Williams

 

Singer Capital Markets (Broker)

Charles Leigh-Pemberton / James Fischer

 

T: 0203 328 5656

 

 

T: 0207 496 3000

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOALIMPTMTMTBBA
Date   Source Headline
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company
28th Apr 20217:01 amRNSTrading update
28th Apr 20217:00 amRNSExscientia Series D funding led by SoftBank
20th Apr 20217:00 amRNSHolding(s) in Company
24th Mar 20217:00 amRNSUnaudited Half Year Results
19th Mar 20217:00 amRNSFieldwork Robotics raises £675,000
18th Mar 20217:00 amRNSHolding(s) in Company
16th Mar 20217:00 amRNSAlusid - appoints David Taylor CBE to the Board
12th Mar 202112:27 pmRNSHolding(s) in Company
12th Mar 20217:00 amRNSHolding(s) in Company
11th Mar 20217:00 amRNSinSignals Neurotech receives EUR100,000 investment
9th Mar 20217:00 amRNSUN awards $250,000 grant to AquaInSilico
8th Mar 20219:05 amRNSSecond Price Monitoring Extn
8th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:30 amRNSExscientia completes $100 million Series C funding
22nd Feb 20217:00 amRNSPulsiv Solar raises £890,000
16th Feb 20217:00 amRNSPublication of newsletter
16th Feb 20217:00 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSFrontier IP supports breakthrough technology
18th Jan 20217:00 amRNSHolding(s) in Company
15th Jan 20217:00 amRNSAppointment of Darren Winter
11th Jan 20217:00 amRNSPortfolio news – Elute Intelligence raises £250k
29th Dec 20201:44 pmRNSHolding(s) in Company
17th Dec 202012:30 pmRNSResult of AGM
1st Dec 20207:00 amRNSCambridge Raman participates in EUR 5m project
20th Nov 20207:00 amRNSPosting of Annual Report and Notice of AGM
16th Nov 20207:00 amRNSFrontier IP: recording of annual results webcast
16th Nov 20207:00 amRNSPortfolio news – Fieldwork SIF grant
13th Nov 20202:03 pmRNSHolding(s) in Company
10th Nov 20207:00 amRNSAlusid - £125,000 backing from UK Future Fund
9th Nov 20206:03 pmRNSDirectors’ Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.